XORTX Therapeutics Gain 87% Following Publication of Research Supporting Treatment Pipeline

By MarketWatch | Aug 29, 2024 at 03:07 PM EST

XORTX Therapeutics' stock surged 87% to $2.15 after recent research on genetic regulation of xanthine oxidase supporting their treatment approach for kidney and other diseases. The company plans to present at the American Society of Nephrology's Kidney Week in October.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.